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Abstract: Metastatic events to the bone occur frequently in numerous cancer types such as 
breast, prostate, lung, and renal carcinomas, melanoma, neuroblastoma, and multiple myeloma. 
Accumulating evidence suggests that the inflammatory cytokine interleukin (IL)-6 is frequently 
upregulated and is implicated in the ability of cancer cells to metastasize to bone. IL-6 is able to 
activate various cell signaling cascades that include the STAT (signal transducer and activator 
of transcription) pathway, the PI3K (phosphatidylinositol-3 kinase) pathway, and the MAPK 
(mitogen-activated protein kinase) pathway. Activation of these pathways may explain the ability 
of IL-6 to mediate various aspects of normal and pathogenic bone remodeling, inflammation, 
cell survival, proliferation, and pro-tumorigenic effects. This review article will discuss the role 
of IL-6: 1) in bone metabolism, 2) in cancer metastasis to bone, 3) in cancer prognosis, and 4) 
as potential therapies for metastatic bone cancer.
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Introduction
Bone homeostasis is maintained by a variety of cell types that control remodeling of the 
bone matrix. Two important cell types that mediate bone homeostasis are osteoblasts 
and osteoclasts. Osteoblasts contribute to the bone matrix by production of type I 
collagen, deposition of hydroxyapatite crystals into the collagen matrix, and regula-
tion of osteoclast activity.1,2 Osteoblasts are of mesenchymal origin and differentiate 
from pre-osteoblasts. This process occurs via bone morphogenic proteins (BMPs) that 
induce runt-related transcription factor 2 (Runx2), leading to increased alkaline phos-
phatase activity.1 Conversely, osteoclasts resorb bone matrix3 and differentiate from the 
hematopoietic cell lineage upon stimulation in a differentiation process called osteo-
clastogenesis. Osteoclastogenesis is mediated by cytokines such as receptor activator 
of nuclear factor (NF)-κB ligand (RANKL) and macrophage-colony stimulating factor 
(m-CSF) (Figure 1A).3,4 RANKL, a membrane-bound ligand, and m-CSF a secreted 
factor, are predominantly produced by osteoblasts.5 Osteoclastogenesis is regulated 
primarily via RANKL and osteoblast-produced osteoprotegrin (OPG) expression, a 
decoy receptor to RANKL that suppresses RANKL activity.6 Osteoblasts that express 
RANKL have cell-to-cell contact with osteoclasts via ligand-receptor binding between 
RANKL and RANK (receptor activator of NF-κB) expressed on osteoclasts.7 RANKL 
functions to promote osteoclast differentiation and activity through stimulation of various 
pathways including the phosphatidylinositol-3 kinase (PI3K) pathway and the mitogen 
activated protein kinase (MAPK) pathway. The MAPK pathway leads to the activation 
of c-fos, nuclear factor of activated T-cells-2 (NFAT2), and other   transcription factors.8,9 Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Figure 1 Model of osteoclastogenesis during bone homeostasis and tumor cell metastasis to bone. A) In normal bone, RANKL and m-CSF are produced primarily by 
osteoblasts. m-CSF binds to its receptor c-FMS, expressed on osteoclast progenitors, and RANKL binds to its receptor on pre-osteoclasts to promote osteoclastogenesis. 
Osteoprotegrin, also produced by osteoblasts, acts as a decoy receptor for RANKL and negatively regulates osteoclast differentiation. In this model, osteoblast and osteoclast 
activity are in homeostasis through careful regulation of osteoclastogenesis. B) When cancer cells metastasize to the bone, increased IL-6 may be produced by both the 
cancer cells and the osteoblasts, as an inflammatory response to the cancer cells. IL-6 then stimulates various types of stromal cells in the bone, which include bone marrow 
cells, osteoblasts, and fibroblasts in the area of the metastasis, to increase the expression of RANKL and m-CSF by osteoblasts. This IL-6-mediated increase in RANKL 
and m-CSF also occurs with injury and inflammation to the bone, but unlike in cancer metastasis, it is transient. RANKL and m-CSF then, in turn, activate the osteoclast 
differentiation cascade, where m-CSF strongly stimulates early stages of osteoclast differentiation, and RANKL stimulates late stages of osteoclast differentiation, as well as 
osteoclast activity. Once this occurs, osteoclast activity becomes dysregulated and reduces bone integrity. 
Abbreviations: c-FMS, colony stimulating factor 1 receptor; IL-6, interleukin 6; IL-6R, IL-6 receptor; m-CSF, macrophage-colony stimulating factor; RANKL, receptor 
activator of nuclear factor κB ligand; sRANKL, soluble form of RANKL.
Cleavage of RANKL from the cell membrane by proteinases 
such as matrix metalloproteinase-7 (MMP7) yields the soluble 
form of RANKL (sRANKL), which has a physiological 
function that is still disputed, although both anti- and pro-
osteoclastogenic effects have been reported.5,10–12
As osteoclasts differentiate in response to pro-osteoclastic 
factors, these cells create a segregated zone, a sealed area 
between the osteoclast and the bone matrix.9 Osteoclasts then 
release hydrogen ions into the segregated zone, solubilizing 
the hydroxyapatite crystals and promoting acid-activated Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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proteinases such as cathepsin K to degrade the collagen 
matrix.9,13 Osteoblasts generate new matrix to fill the vacant 
area. The rate at which osteoclasts differentiate and resorb 
bone is carefully regulated by osteoblast-produced RANKL 
and OPG. Other cells in the bone matrix such as osteocytes, 
terminally differentiated osteoblasts, are able to regulate 
the generation and resorption of bone matrix by affect-
ing osteoblast and osteoclast activity.14 When osteocytes 
are mechanically stimulated by shock to bone resulting in 
dynamic fluid movement, they promote alkaline phosphatase 
activity in osteoblasts by cell-to-cell contact through the 
RANK/RANKL complex, increasing bone mineralization 
and turnover.15–17 In this manner, damaged sections of the 
bone are removed and are replaced with new bone matrix 
by osteoblasts.
In normal bone, homeostasis is maintained and bone 
integrity is preserved by a continuous cycle of bone renewal. 
However, when cancer cells metastasize to the bone, the bal-
anced and complex interplay of the cells is disrupted, leading 
to a pathologic condition that compromises bone integrity. 
One of the many characteristics that bone-homing cancer 
cells have in common is that most of them release copious 
levels of interleukin (IL)-6, which helps in facilitating bone 
invasion and growth of metastatic lesions.18–20 In this review 
article, the role of IL-6 in facilitating bone metastasis and 
approaches to measure serum IL-6 to predict progression of 
metastatic disease will be discussed.   Additionally, new thera-
pies targeting IL-6 and their potential efficacy in preventing 
bone metastasis will be reviewed.
Frequency, consequences,  
and mechanisms of cancer  
cell metastases to bone
Various types of cancers metastasize to the bone, including 
breast, prostate, lung, thyroid, kidney, multiple myeloma, 
melanoma, and neuroblastoma.21–25 Usually the bone is only 
compromised at the site of metastasis, and not all types of 
bone metastases affect the bone in the same way. For example, 
breast cancer predominantly causes osteolytic lesions, result-
ing in an upregulation of osteoclast activity and subsequent 
decreased bone density and integrity that may lead to 
fractures.22,26 Conversely, prostate cancer results in primar-
ily osteoblastic lesions that are caused by cytokine-induced 
upregulation of osteoblast activity and subsequent increased 
bone density.26 This type of bone metastasis causes thickening 
of the bone, resulting in the possibility of nerve compression, 
vertebral fusion, and spinal cord compression depending on 
the location of the metastases. In contrast to what is found in 
normal bone where collagen fibers are highly organized and 
tightly packed, bone created by osteoblastic lesions contains 
disorganized and fragile collagen fibrils.27 This leads to a high 
degree of bone brittleness, increase in potential fractures, 
and pain as the normal bone is replaced by abnormal bone 
created by the osteoblastic lesions. A subset of prostate 
cancers may also cause osteolytic lesions due to the expres-
sion of different cytokines that promote osteoclast activity 
rather than osteoblast activity.28 Multiple myeloma causes 
only osteolytic lesions. Other cancers, including lung, kidney, 
and thyroid carcinomas, result in primarily osteolytic lesions, 
but osteoblastic lesions occur occasionally.26,29 Metastasis 
of the primary tumor to the bone occurs in about 60%–75% 
of patients with metastatic breast cancer, prostate cancer, 
neuroblastoma, or multiple myeloma.21–23,30 Metastases to the 
bone from other cancers such as lung, kidney, and thyroid 
only occur in 30%–50% of patients with metastases.24
The molecular mechanisms that determine when a cancer 
cell will metastasize to bone are not completely understood. 
Recent evidence shows that the CXC chemokine receptor 4/
chemokine (C-X-C motif) ligand 12 CXCR4/CXCL12 axis 
may play a role in this metastatic process. Studies have dem-
onstrated that cancer cells are attracted to the bone   marrow 
due to the relatively high levels of CXCL12 expressed by 
osteoblasts, which acts as an attractant for the CXCR4 ligand-
positive cancer cells.31 Numerous studies have demonstrated 
that bone metastatic cancer cells from the breast, prostate, and 
myeloma overexpress the CXCR4 ligand, which promotes 
homing and metastasis to the bone and other organs.32–35 
Inflammatory cytokines, such as IL-6, increase CXCR4 
expression in breast cancer cells, specifically in a signal 
transducer and activator of transcription 3 (STAT3), and 
c-Jun-dependent manner.36 Given these findings, therapeu-
tics designed to block the CXCR4/CXCL12 axis are being 
evaluated in the prevention of bone metastases.37
Once cancer cells colonize in the bone, they have to adapt 
to the challenges of cell survival and growth in a foreign 
tissue environment. The bone is a reservoir of a complex 
mixture of growth factors38 that are released as the bone is 
degraded by metastatic lesions. The mixture of these growth 
factors include transforming growth factor (TGF)-β, insulin 
like growth factor (IGF)-1, insulin-like growth factor (IGF)-2, 
platelet derived growth factor (PDGF), bone morphogenic 
proteins (BMP), fibroblast growth factors (FGF), and other 
factors that significantly improve tumor cell survival and 
growth.39 These factors can promote the expression of pro-
survival signals such as B-cell lymphoma 2 (Bcl-2) and AKT, 
which inhibit apoptosis in the cancer cells. In addition, these Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
180
Tawara et al
factors can also support further osteoclast differentiation 
and activity, leading to a vicious positive feedback loop (the 
vicious tumor–bone cycle) where additional growth factors 
are released, stimulating increased cancer cell growth and 
accelerated bone destruction. This accelerated bone destruc-
tion can lead to rapid loss of bone integrity in cancer patients 
causing fractures, pain, and loss of mobility.
IL-6, other cytokines, and 
growth factors in the bone 
microenvironment
IL-6 is a major pleiotropic, pro-inflammatory cytokine 
which plays a role in immune response, hematopoiesis, 
cell differentiation, wound repair, and bone remodeling.40,41 
  Inflammation in the bone caused by injury or disease 
increases expression of IL-6 by reactive stromal cells of the 
bone and infiltrating monocytes and macrophages, promoting 
bone remodeling evidenced by higher osteoclast activity.42 
The reactive stromal cells for bone metastases are generally 
the mesenchymal stem cells in the bone marrow as well 
as the fibroblasts, osteoblasts, and osteocytes in the region. 
IL-6 production is directly stimulated by prostaglandin E2 
(PGE2) and TGF-β, while IL-1β and lipopolysaccharides 
indirectly stimulate IL-6 production via NF-κB activation 
(Figure 2).43–48 IL-6 binds to its heterotrimeric receptor, con-
sisting of two gp130 subunits and an IL-6 receptor subunit, 
on target cells and activates the STAT, MAPK, and PI3K 
pathways.49–52 IL-6 signaling through the Janus kinase (JAK)/
STAT3 pathways lead to expression of RANKL from osteo-
blast/stromal cells, causing direct stimulation of osteoclast 
differentiation and activity and resulting in bone destruction 
(Figure 3).53,54 Studies using IL-6 knockout mice have dem-
onstrated that IL-6 is necessary for upregulating osteoclast 
activity and bone resorption in vivo. IL-6 knockout mice were 
shown to be protected from increased osteoclast activity and 
subsequent bone degradation when their bones were injected 
with the arthritis-inducing antigen heat-killed Mycobacterium 
tuberculosis.55 IL-6 knockout bones that received antigen 
injections had less RANKL and IL-17 expression as well 
as reduced osteolysis and cartilage destruction near the site 
of injection compared with wild-type mice. IL-17 is a pro-
inflammatory and pro-osteoclastogenic cytokine implicated 
in arthritis and tumorigenesis that is produced in CD4+ helper 
and tumor infiltrating T-cells when activated by IL-6.56,57 
Additional mouse studies have demonstrated that inhibition 
of IL-6 activity, with an IL-6 receptor (IL-6R) antagonist 
that inhibits downstream receptor signaling, reduces bone 
resorption.58 These results suggest that IL-6 plays a major 
role in the upregulation of additional pro-osteoclastic factors 
essential for osteoclast activity.
Deregulation of IL-6 expression is implicated in disorders 
of bone homeostasis such as osteoporosis and osteopetrosis. 
Sex hormones such as 17-β-estradiol and testosterone have 
been shown to regulate IL-6 levels in the bone microenviron-
ment. 17-β-estradiol is known for its bone-preserving effects, 
which is supported by the fact that post-menopausal women 
experience a decrease in bone mineralization and density 
that may lead to osteoporosis.59 A recent study shows that 
17-β-estradiol reduces both IL-6 and IL-8 production by 
monocytes and multiple myeloma cells through a   mechanism 
Interleukin-6
upregulating
stimuli
Infection
Injury
Inflammation
Cyclooxygenase-2 (COX-2)
NFκB independent
NFκB dependent
Interleukin 1 Beta (IL-1β)
Lipopolysaccharides (LPS)
Prostaglandin E2 (PGE2)
Transforming growth factor beta (TGFβ)
IL-6 production
Cancer
Nuclear factor kappa B (NFκB)
Figure 2 Factors that increase IL-6 production in response to various stimuli. Increased IL-6 production is associated with stimuli such as infection and inflammation. 
Infection, injury, and cancer can all stimulate inflammation that can lead to the increase of IL-6-modulating factors such as IL-1β, COX-2, PGE2, and TGF-β. Infection can 
also promote LPS secretion from bacteria, which increases NF-κB-dependent IL-6 levels. There are two main IL-6 production pathways: NF-κB-dependent and NF-κB-
independent. NF-κB-independent pathways upregulate IL-6 secretion via TGF-β or PGE2, which is produced downstream of COX-2 activation. In the NF-κB-dependent 
pathway, LPS or IL-1β stimulate NF-κB activity that causes an increase in IL-6 production. 
Abbreviations: COX-2, cyclooxygenase 2; IL-1β, interleukin 1β; IL-6, interleukin 6; LPS, lipopolysaccharide; NF-κB, nuclear factor κB; PGE2, prostaglandin E2; TGF-β, 
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Figure 3 Model of canonical IL-6 signaling versus IL-6 trans-signaling in tumor progression and metastases. In the canonical IL-6 signaling pathway, the IL-6 receptor subunit 
is membrane bound and forms a heterotrimer with two gp130 subunits. When IL-6 binds to the receptor, STAT3 is activated in a JAK-dependent manner that leads to 
increased RANKL expression. IL-6 may also activate AKT via increased JAK-dependent PI3K activity and result in cell survival and anti-apoptosis signaling. Concomitantly, 
increased MAPK activity downstream of JAK activation can lead to upregulated cell growth, proliferation, and mitosis. In the IL-6 trans-signaling pathway, IL-6 first binds to 
the truncated sIL6R. The IL-6/sIL6R complex then binds to the membrane-bound gp130 dimer to form an IL-6 trans-signaling complex. Due to the fact that the sIL-6R lacks 
a membrane signaling domain, there appears to be significant differences in the intracellular signaling pathways. While IL-6 trans-signaling also leads to phosphorylation and 
activation of STAT3, increased cell survival, proliferation, and mitosis occurs in an AKT-and MAPK-independent manner. The exact mechanisms for IL-6 trans-signaling leading 
to increased cell survival, proliferation, and mitosis are not yet known. 
Abbreviations: IL-6, interleukin 6; JAK, Janus kinase; MAPK, mitogen-activated protein kinase; PI3K, phosphatidylinositol 3-kinase; RANKL, receptor activator of nuclear 
factor κB ligand; sIL6R, soluble IL-6 receptor; STAT3, signal transducer and activator of transcription 3.
that is not yet fully understood.60,61 The chemokine IL-8 is 
also a pro-inflammatory molecule, which like IL-6, can 
increase inflammation in the bone and cause excessive 
bone resorption by upregulating the transcription factor 
NF-κB.62,63 In turn, increased NF-κB activity stimulates 
IL-6 expression and secretion into the extracellular matrix.64 
Studies have shown that the binding of 17-β-estradiol to the 
estrogen receptor inhibits NF-κB transcriptional activity by 
preventing inhibitor of NF-κB alpha (IκBα) degradation, 
leading to decreased IL-6 expression.60,65 IκBα is normally 
constitutively expressed and bound to NF-κB, thus prevent-
ing the translocation of the transcription factor into the 
nucleus and initiation of the transcription of NF-κB-related 
genes.66 17-β-estradiol has also been shown to suppress Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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IL-6 activity by inhibiting STAT3 through upregulation of 
protein inhibitor of activated STAT3 (PIAS3).67 In addition, 
testosterone decreases IL-6 expression by inhibiting NF-κB 
activity in osteoblasts via the hypothalamic-pituitary-adrenal 
axis, normally a potent stimulator of IL-6 production. Both 
of these result in testosterone-mediated bone-preserving 
effects.68–70 Therapies that involve suppression of testosterone 
and 17-β-estradiol are effective against androgen-dependent 
prostate and breast cancer respectively; however, bone density 
decreases significantly with these therapies leading to an 
increased chance of developing osteoporosis.71
IL-6 production by cancer cells 
and stromal cells in the bone 
microenvironment facilitates 
invasion and metastasis
IL-6 produced by cancer cells initiates a variety of down-
stream signaling cascades that can lead to bone destruction 
(Figure 1B). Many cancer cell types that metastasize to the 
bone endogenously produce and secrete high levels of IL-6. 
On the other hand, other cancer cell types stimulate the 
  surrounding stromal cells to release copious amounts of this 
cytokine. Some cancer cell types such as IL-6-dependent 
multiple myeloma cells do not express IL-6 and rely on the 
bone microenvironment’s reactive stromal cells to produce 
IL-6 in response to the presence of the tumor cells.72 This 
stroma-dependent increase of IL-6 in the extracellular matrix 
may be specific to the microenvironment of the metastasis. 
For example, injection of Walker (W256) mouse mammary 
cancer cells and MatLyLu (MLL) mouse prostate cancer-
like cells into mice has been shown to differentially express 
IL-6 depending on the location.73 Specifically, local injection 
of W256 and MLL cells into the bone causes upregulation 
of IL-6, macrophage colony stimulating factor (m-CSF), 
RANKL, and Dickkopf-related protein 1 (DKK1) in the bone 
stromal cells. DKK1 is a member of the dickkopf family of 
factors that has been shown to be elevated in the bone marrow 
of patients with breast cancer bone metastases.74 However, 
when these cells metastasized to nonosseous organs, there 
was little to no expression of IL-6, m-CSF, RANKL, or 
DKK1, indicating that some cancer cells stimulate surround-
ing cells to release pro-osteoclastic factors only in the bone 
microenvironment.73,75
It has been proposed that cancer cells induce an inflam-
matory response in osteoblasts which may lead to the 
stimulation of osteoclast differentiation and activity.76,77 The 
inflammatory response of osteoblasts in response to cancer 
cell-conditioned medium in vitro has been shown to cause 
an upregulation of PGE2, which induces IL-6 and activates 
osteoclasts via RANKL and PTHrP production.18,74,75 This 
effect was seen in breast cancer cells, oral squamous car-
cinoma cell lines, and in neuroblastoma cells.18,75,76 The 
induction of the inflammatory response to the cancer cell-
conditioned medium may be due to NFκB activation via 
an IL-6-independent mechanism within the osteoblasts.77 
  Suppression of NFκB activity with methylseleninic acid 
reduced cytokine production by osteoblasts in response to 
cancer cell-conditioned medium, which may translate to 
reduced bone destruction in vivo.
IL-6 has been demonstrated to increase RANKL expres-
sion from osteoblasts and thus stimulate osteoclastogenesis. 
However inhibitors of RANKL fail to suppress IL-6-  mediated 
osteoclastogenesis and bone resorption.78,79 This suggests 
that IL-6 has potential redundant pathways that upregulate 
bone destruction and could interfere with the efficacy of 
targeted therapies against RANKL such as denosumab, 
a humanized monoclonal antibody against RANKL.80 
RANKL-independent pathways could mediate IL-6 induced 
osteoclastogenesis. For instance, cancer induced inflamma-
tion leads to the stimulation of NF-κB activity, which initi-
ates IL-6 production (Figure 2). NF-κB activity is also able 
to stimulate cyclooxygenase (COX)-2 activity, which would 
result in the production of PGE2, stimulating more IL-6 
release.81 High levels of PGE2 have been shown to promote 
potent, pro-osteoclastic factors.82 IL-6 may also be inducing 
other pro-osteoclastic factors that functions independently 
from RANKL such as IL-1β.83 IL-1β has also been shown 
to increase NF-κB activity84 that could result in a feedback 
loop that further increases IL-6.
IL-6 and its soluble receptor  
as a prognostic factor for cancers 
that metastasize to bone
Predicting disease outcomes in cancer patients with metasta-
sis to bone is difficult due to the inherent high level of tumor 
cell heterogeneity within a specific type of cancer. Current 
attempts at general prognostics are based mostly on tumor 
grading, staging, and invasive characteristics derived from 
histological and other types of physical analysis of biopsies.85 
Specific, factor-based categorization of cancer is limited 
to a handful of well characterized receptor and antigenic 
tests. For example, prostate specific antigen (PSA) has long 
been used as a prognostic factor to estimate progression of 
prostate cancer.86 Immuno-assays are performed to detect 
receptors for estrogen (ER), progesterone (PR), and human Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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  epidermal growth factor receptor 2 (Her2/neu) to aid in 
directing   treatment strategies for breast cancer.87 Improving 
prediction accuracy by using more prognostic factors can 
hasten the detection of any changes in the progression of 
the disease.
Recently, interest in using serum IL-6 as a specific 
prognostic factor for prostate cancer and breast cancer has 
risen.88–90 Current research demonstrates that serum IL-6 
levels are significantly increased in many cancer patients 
with invasive prostate cancer compared with benign prostatic 
hyperplasia (BPH).91 It has been shown that higher levels 
of serum IL-6 in patients with castration-resistant prostate 
cancer correlates to shortened survival times.92 Serum IL-6 is 
also elevated in prostate and breast cancer patients with distal 
metastases compared with patients without metastases,92,93 
and higher serum IL-6 levels have been associated with 
lower patient survival rates in metastatic breast and prostate 
cancer.94 The spread of breast cancer cells into the local lym-
phatic system is also significantly correlated with increased 
IL-6 levels.93 Other studies have supported these findings 
and have shown that IL-6 correlates with the extent and size 
of prostate cancer bone metastases; specifically, the larger 
and more compromised the bone was, the higher the level 
of serum IL-6.95,96 Furthermore, significant elevation of IL-6 
levels in the serum have been seen in prostate cancer patients 
who have experienced a relapse, where IL-6 levels positively 
correlate with cachexia.90,97 Additionally, IL-6 levels have 
been shown to correlate with measures of morbidity and poor 
patient health.98 In one case study, a sharp increase in serum 
IL-6 was detected in terminally ill cancer patients who were 
experiencing extreme cachexia.99
A comprehensive study involving patients with metastatic 
gastric cancer, which can also metastasize to the bone,100,101 
demonstrated a significant correlation between serum 
IL-6 levels and the extent of gastric cancer progression.102 
  Specifically, IL-6 levels correlated with tumor grade and the 
extent of invasion into the gastric organ as well as lymphatic 
and hepatic systems. Long-term survival rates were much 
higher with patients that had low levels of serum IL-6, and 
post-surgical probability of metastasis was higher in patients 
with high serum IL-6.102 The use of serum IL-6 levels for 
prognosis in a clinical setting is limited by gaps in the cur-
rent understanding of mechanisms by which IL-6 specifically 
mediates the progression of metastatic disease as well as a 
lack of large clinical trials to assess baseline and range of 
fluctuation of serum IL-6 levels.
In addition to serum IL-6 levels, the concentration of 
soluble receptor to IL-6 (sIL-6R) in the serum may also help 
predict the aggressiveness of cancer metastasis and the level 
of bone destruction. Even in the absence of cancer, high levels 
of serum concentration of sIL-6R can predict the rate and 
level of osteolysis in patients with   hyperparathyroidism.103 
High levels of sIL-6R in the serum have also been associated 
with increased generalized inflammation, rheumatoid arthri-
tis, inflammatory bowel disease, asthma, and inflammation-
associated colorectal cancer.104 sIL-6R enables a process 
called IL-6 trans-signaling, where cells that do not possess 
IL-6 receptor, or have low levels of it, can respond to IL-6 
(Figure 3). This occurs through an unclear mechanism by 
incorporating the sIL-6 receptor into the gp130 receptor 
dimer on the cells, forming a IL-6 receptor heterotrimer 
and enabling the cells to respond to IL-6.105 Interest in 
IL-6 trans-signaling has increased in the past several years 
as new research show that sIL-6R is produced by various 
cancer cells, and the serum concentration is associated 
with decreased survival and increased aggressiveness of 
metastases in breast, prostate, and colorectal cancers.95,106,107 
Some data suggest that IL-6 trans-signaling causes various 
effects that promote cancer metastases including, increased 
detachment, proliferation, and migration through a path-
way that is independent of STAT1, STAT3, or MAPK.108 
This suggests that IL-6 trans-signaling is distinct from the 
canonical IL-6 signaling pathway and could be due to the 
lack of the membrane signaling domain on the sIL-6 recep-
tor subunit (Figure 3). However, IL-6 trans-signaling does 
cause increased RANKL expression in synovial fibroblasts 
through a STAT3-dependent manner,53 which suggests that 
trans-signaling may use some of the canonical IL-6 pathway 
to exert its effects. Although there is a convincing amount 
of evidence to suggest that higher serum sIL-6R levels may 
be associated with a worse cancer prognosis, little is known 
about the specifics of the IL-6 trans-signaling pathway, and 
more studies need to be done before assessing whether sIL-6R 
is a therapeutic target.
Serum IL-6 levels may predict  
response to cancer therapy
It is critical to determine throughout a patient’s treatment 
whether the current therapy plan should be maintained or 
whether new therapies need to be initiated. Changes in 
serum IL-6 levels in patients undergoing chemotherapies or 
targeted therapeutics may act as a biomarker that can predict 
whether a patient is responding or not. In one clinical study, 
combination therapy using docetaxel and zoledronic acid, a 
bisphosphonate that inhibits osteoclastic activity, was admin-
istered to prostate cancer patients with bone metastases.109 Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Patients that responded to the therapy had a 35% decrease in 
overall serum IL-6 levels, while patients that did not respond 
had a 76% increase in serum IL-6 levels.109 A confounding 
variable in this finding is that some of the increase in serum 
IL-6 may be due to a stress response to the chemotherapeutic 
agents themselves, and the high levels of IL-6 may actually 
confer drug resistance.110 However, IL-6 has also been cor-
related to C-reactive protein (CRP) levels in the serum, and 
reduction in CRP levels alone may indicate positive biologic 
effects of chemotherapeutics indicated by a reduction in serum 
IL-6.111,112 Although there is a dearth of clinical studies using 
IL-6 as a predictive biomarker of therapeutic response, initial 
studies support the concept that changes in serum cytokine 
levels such as IL-6 are worthy of more investigation.
IL-6 promotes chemotherapy 
resistance
Chemotherapeutics traditionally have been and are currently, 
a mainstay in therapies against metastatic disease. However, 
resistance to chemotherapeutics is common, and the mecha-
nisms mediating resistance have been difficult to determine. 
Recent experimental results suggest that chemotherapy resis-
tance is mediated through a relatively heterogeneous set of 
mechanisms, including downregulation of apoptotic signals, 
increased drug clearing and deactivation from cancer cells, 
multidrug resistance gene mutations, and stimulation of cell 
survival pathways via gene amplification.113–115
A substantial amount of chemotherapy resistance research 
presently focuses on upstream mediators of cell survival. In 
the bone microenvironment, high concentrations of IL-6 have 
recently been shown to confer resistance to apoptosis in breast 
and prostate cancer cells as well as neuroblastoma cells.18,116,117 
Specifically, prostate cancer cell activity of NF-κB has 
been shown to cause high IL-6 production, which promotes 
docetaxel resistance in prostate tumors and associated bone 
metastases by upregulating the pro-survival AKT pathway 
in an IL-6-dependent manner (Figure 3).49 Additionally, 
resistance to paclitaxel is observed in breast cancer patients 
whose metastatic lesions show high levels of IL-6.115 This high 
IL-6 production could itself be a f  unction of the cancer cell’s 
response to   chemotherapeutics. One particular study presented 
evidence that paclitaxel induced expression of IL-6 in cervical 
cancer cells via the c-Jun N-terminal kinase (JNK) signaling 
pathway.110 More studies need to be conducted to assess the 
full role of IL-6 in conferring chemotherapeutic resistance, 
but these preliminary studies may support a rationale for using 
combination therapy of IL-6 inhibitors along with classical 
chemotherapeutic agents.
IL-6 as a target for therapy
Currently, the only kinds of therapies that can treat bone 
metastases are supportive therapies using 1) bisphosphonates 
to reduce osteolytic burden, 2) radiotherapy and analgesics 
to alleviate pain, and 3) surgical intervention to reinforce 
weak bones.24,118,119 The humanized monoclonal antibody 
to the IL-6 receptor, tocilizumab (Actemra®) was approved 
by the United States Food and Drug Administration (FDA) 
on   January 11, 2010 and was previously approved in Japan 
and the European Medicines Agency (EMEA) in 2008 
(Table 1).120 Although tocilizumab is approved only for rheu-
matoid arthritis (RA) in the United States and Europe as well 
as Castleman’s disease in Japan, recent studies have shown 
that tocilizumab is also effective as an antitumor agent against 
U87MG glioma cells. Tocilizumab exerts an inhibitory 
effect on the JAK/STAT3 pathway by preventing IL-6 from 
binding to its receptor, thereby inhibiting IL-6 signaling.121 
Similar antitumor effects were seen with S6B45 multiple 
myeloma cells where a modified version of tocilizumab 
significantly inhibited the proliferation of these cells in 
vitro.122   Tocilizumab has also been effective in blocking 
cartilage and bone destruction in IL-6-mediated autoimmune 
diseases such as synovitis and RA, where the mechanism of 
bone destruction is similar to that of bone metastases and 
high, local IL-6 levels were reported.123 Thus, tocilizumab 
may be effective as part of a combination therapy with bis-
phosphonates to control cancer cell-mediated destruction of 
the bone. However, there is no public data that exists for the 
efficacy of tocilizumab in inhibiting the progression of bone 
metastases. Other inhibitors of IL-6 activity for the treatment 
of various autoimmune diseases such as lupus, RA, Crohn’s 
disease, and Castleman’s disease are being developed or are 
undergoing FDA approval.
Another anti-IL-6 drug that is being developed for 
bone metastatic prostate and renal carcinomas and mul-
tiple myeloma is (Centocor’s) CNTO-328 (Siltuximab).124 
This chimeric, monoclonal antibody to IL-6120,125 recently 
completed initial clinical trials for prostate cancer, kidney 
cancer, and renal cell carcinoma with mixed results. Some 
preliminary results from the completed trials indicate 
minimal side effects with the inhibitor; however, there was 
a general lack of correlation with IL-6 inhibition and reduc-
tion in tumor growth.125,126 The lack of tumor inhibition may 
be due to the nature of the trial that attempted to ascertain 
the safety profile of the drug, thereby leading to the use of 
a lower dose than may be effective. However, new clinical 
trials with dose escalation are planned. On the other hand, 
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Table 1 Targeted therapies for IL-6
FDA approval status Drug manufacturer Drug name Drug type Reference
Approved drugs
Approved for rheumatoid 
arthritis
Roche and Chugai Tocilizumab Monoclonal humanized  
antibody to IL-6 receptor
Melton L et al120
Kudo M et al121
Promising drugs in trials
Phase 2 trials prostate cancer, 
multiple myeloma
Centocor CNTO-328 Monoclonal chimeric  
antibody to IL-6
Melton L et al120
Zaki MH et al128
Phase 1 trials completed and  
Phase 2 trials pending
Avida, purchased by Amgen C326 or AMG-220 Avimers Silverman et al133
Sheridan C132
is still ongoing. Preliminary results from a Phase 2 trial on 
these patients demonstrate positive results with manageable 
side effects and good safety profile.127 This is supported by 
a study showing that siltuximab can inhibit prostate cancer 
cell growth in vitro and improve survival by reducing the 
level of cachexia in an animal model of prostate cancer.128 
In addition, siltuximab has been shown in mice to inhibit 
the conversion of androgen-dependent prostate cancer into 
a more aggressive, bone metastatic, and difficult to treat 
androgen-independent prostate cancer.129 Treatment with 
siltuximab also decreased serum CRP levels, which cor-
related to improved outcome in treatment-resistant prostate 
cancer.112 Other recent data indicate that STAT3 and MAPK 
activity is suppressed in patients taking siltuximab, which 
may inhibit IL-6 mediated drug resistance.130 However, in a 
separate Phase 2 clinical trial involving castration-resistant 
prostate cancer where the disease had progressed beyond 
docetaxel therapy, siltuximab had a minimal clinical effect, 
despite positive biological IL-6 inhibition.131 New clinical 
trials using a combination of siltuximab and chemothera-
peutics such as docetaxel are underway.131
The use of antibodies for therapeutically inhibiting 
cytokines such as IL-6 may soon be replaced by utilizing 
small protein, nonantibody-based inhibitors called avimers. 
Avimers may surpass monoclonal antibodies in efficacy 
and potency, while reducing cost. Because these proteins 
lack immunoglobulin domains, they are much less immu-
noreactive, and their smaller size (∼4 kDa) allows tighter 
interactions between the avimer and their target cytokine or 
receptor.132,133 In addition, due to their reduced immunoreac-
tive nature, they should theoretically reduce occurrences of 
serious side effects such as acute allergic reactions, which 
currently are a common problem with antibody therapeutics. 
Because of the promising features of this type of biological 
therapeutic, many pharmaceutical companies are pursuing 
the development of drugs based on nonantibody protein 
compounds, but the majority of these compounds are still in 
preclinical or Phase 1 trials.
Avida recently developed an avimer against IL-6 called 
C326 or AMG-220.134 Their studies show that this avimer 
has superior stability and drug longevity compared with anti-
body-based inhibitors,73 resulting in an increase in both the 
half-life and the shelf-life of the drug. Avida published results 
demonstrating that their avimer against IL-6 has an IC50 in 
the picomolar range leading to much smaller doses, and as 
it can be produced in Escherichia coli, the cost is reduced.133 
AMG-220 is also being developed for Castleman’s disease, 
an autoimmune disorder that is characterized by high levels of 
serum IL-6 which is thought to cause the hyper-proliferation 
of B-cells, leading to high fevers, joint pain, weight loss, 
and anemia.135 Currently, a Phase 1 trial for Crohn’s disease 
is also in progress and is recruiting volunteers with stable 
disease and generally good health.133,136,137
Although not all IL-6 inhibitors currently being developed 
or on the market are designed for cancer, IL-6 inhibitors, in 
principle, should work similarly for all diseases where IL-6 is 
deregulated. Therefore, IL-6 inhibitors should effectively inhibit 
IL-6-dependent cancers by reducing metastases to the bone and 
bone destruction. Availability of IL-6 inhibitors for the treatment 
of various cancers and bone metastases should improve as new 
uses of the inhibitors are approved by the FDA.
Conclusion
Recent research and publications have demonstrated that 
IL-6 is one of the major factors upregulating and modulating 
cancer-mediated bone destruction. The information presented 
in this review illustrates the potential for IL-6 as a prognostic 
factor. In addition, fluctuations in serum IL-6 levels could 
help direct additional treatment strategies in the future, but 
clinical studies are needed to assess that potential. There is 
also evidence from in vitro, in vivo, and preliminary clinical 
trials to suggest that specific anti-IL-6 therapies may improve 
cancer survival rates and reduce metastatic burden in some 
types of cancers. However, additional studies and appropriate 
clinical trials need to be done to fully ascertain the effective-
ness of anti-IL-6 therapies in cancer patients.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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